Connection

David Taber to Combined Modality Therapy

Back to Details
This is a "connection" page, showing publications David Taber has written about Combined Modality Therapy.
David Taber
Connection Strength
0.030
Combined Modality Therapy
  1. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200?days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study. Transpl Infect Dis. 2017 Dec; 19(6).
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.